ARTICLE | Management Tracks
Obsidian fills CEO, CDO roles with Iovance vets
Plus: Jami Rubin joins Arch, and updates from Exo, Harbinger, Twist and more
May 23, 2023 11:14 PM UTC
Cell and gene therapy company Obsidian Therapeutics Inc. hired Madan Jagasia as CEO and Parameswaran Hari as chief development officer. Both were most recently at Iovance Biotherapeutics Inc. (NASDAQ:IOVA), where Jagasia was EVP, medical affairs, and Hari was SVP, clinical science.
Jami Rubin became a venture partner at Arch Venture Partners. Rubin was CFO at EQRx Inc. (NASDAQ:EQRX) and is a 20-plus-year veteran of Goldman Sachs, where she covered the biopharma industry as an equity analyst...
BCIQ Company Profiles
BCIQ Target Profiles